PHAT

Phathom Pharmaceuticals, Inc. (PHAT) | Rumor.io

Phathom Pharmaceuticals

PHAT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,017

Bullish sentiment (50-day avg)63%

Price to earnings ratio-2.42

Market capitalization594.6M

Earnings per share-1.25

Dividend yield (TTM)—

Revenue (annual)175.1M

Net income (annual)-221.2M

Social

What share of all stock conversation is about PHAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 23

The company's stock price has been subject to significant volatility, with some users expressing frustration and others seeing opportunities for purchase.
There is a disconnect between the company's fundamentals and its current market value, with some users questioning the basis for the current valuation.
The company's management is expected to provide updates on new indications and a robust growth strategy, which some users believe will add significant value to the company.

Generated by AI

Sentiment

Of the messages about PHAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	27.78% -33.99	55.29% -13.54	80.43% +1.54
Bearish	—	72.22% +33.99	44.71% +13.54	19.57% -1.54

Bullish· Oct 30

Phathom Pharmaceuticals, Inc. has reported a 25% quarter-over-quarter increase in net revenues, reaching $49.5 million.
The company has successfully reduced cash operating expenses by 43% quarter over quarter, which, combined with revenue growth, has impressed investors and analysts.
With guidance for full-year 2025 revenue of $170-$175 million and expectations to achieve operating profitability in 2026, Phathom Pharmaceuticals is seen as a strong candidate for continued growth and potential price appreciation.

Bearish· Jun 11

$PHAT's inability to break resistance at $9.50 suggests it's heading downwards.
Phathom Pharmaceuticals has no money, with a public offering expected soon, potentially leading to dilution.
The company's core metrics remain ugly, with unprofitability, over-leveraging, and cash burn, despite a recent exclusivity agreement.

Generated by AI

Topics

Of the messages about PHAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	25.47%
Announcements	—	—	0%	39.66%
Earnings	—	—	0%	16.24%
Analysts	—	—	0%	18.46%
Controversies	—	—	0%	0.17%
Macro	—	—	0%	0%

Jan 8

Phathom Pharmaceuticals priced a $130 million public offering of common stock and pre-funded warrants at $16 per share.
The company will use the funds from the offering for operations, research and development, and product rollout.
Phathom Pharmaceuticals' shares fell by 13.6% after pricing the stock offering at a discount.

Generated by AI

Community

Of the messages about PHAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.68%	79.5%	54.53%
Newcomers	0%	11.32%	20.5%	45.47%

Regulars· Aug 4

The stock price may be due for a boost, potentially driven by upcoming trial results or a catalyst for the company's performance.
Analysts still have targets of $20 for the stock, despite the current sell-off, and the quarterly report did not fundamentally change the company's trajectory or results.
The recent selloff is seen as "comical" compared to the company's actual results and trajectory, with some investors hoping for the stock to stay around $8.5 for a couple of months.

Newcomers· Mar 2

Newcomers to the $PHAT community are discussing its market capitalization, specifically its value sitting at around $65k and how it's approaching its all-time high.
Recent investors are focused on Phathom Pharmaceuticals' upcoming Q4 2025 Earnings Call, with some speculating on what the company's financial results may reveal.
Many newcomers are concerned about the company's ability to maintain its current price level, as some have expressed skepticism about the stock's sustainability in reaching new all-time highs.

Generated by AI

News

Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD

11h agoInvesting.com

Phathom starts phase 3 trial of Voquezna for heartburn relief

22h agoInvesting.com

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT)

20d agoSeeking Alpha

Phathom at Cantor conference: growth, access and new uses

20d agoInvesting.com

Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT

Phathom Pharmaceuticals (PHAT) has an average rating of Buy and mean price target of $23.70, accordi

21d agoYahoo Finance

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September: 2026 Cantor Global Healthcare Conference in New York, NYDate: Wednesday, September 9, 2026Fireside Chat: 10:55 am EDTManagement to par

28d agoYahoo Finance

Also Discussed

Investors talking about PHAT also mention

#	Name	Attention
1	Nurix Therapeutics, Inc.NRIX	0%new
2	SWTX - SpringWorks Therapeutics, Inc.	——
3	Autolus Therapeutics plc ADRAUTL	0%+0
4	Silence Therapeutics Plc ADRSLN	0.01%new
5	Neurogene Inc.NGNE	0%0
6	Verrica Pharmaceuticals Inc.VRCA	0%0
7	KRON - Kronos Bio, Inc.	——
8	MCTR - CTRL Group Limited Ordinary Shares	——
9	Travere Therapeutics Inc.TVTX	0%0
10	Abivax SAABVX	0.01%-0.01

Phathom Pharmaceuticals, Inc.

Healthcare
Biotechnology

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s commercial portfolio centers on vonoprazan-based therapies, including VOQUEZNA for the relief of heartburn associated with non-erosive and erosive GERD and the healing and maintenance of erosive GERD in adults. It also markets VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for the treatment of Helicobacter pylori infection in adults. Phathom Pharmaceuticals operates as a specialist in acid-related GI disorders, combining research, product development, and commercialization to address conditions that affect the digestive system.

Website

Location

100 Campus Drive

Florham Park, NJ, 07932

United States

Social

What share of all stock conversation is about PHAT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 23

The company's stock price has been subject to significant volatility, with some users expressing frustration and others seeing opportunities for purchase.
There is a disconnect between the company's fundamentals and its current market value, with some users questioning the basis for the current valuation.
The company's management is expected to provide updates on new indications and a robust growth strategy, which some users believe will add significant value to the company.

Generated by AI

Sentiment

Of the messages about PHAT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	27.78% -33.99	55.29% -13.54	80.43% +1.54
Bearish	—	72.22% +33.99	44.71% +13.54	19.57% -1.54

Bullish· Oct 30

Phathom Pharmaceuticals, Inc. has reported a 25% quarter-over-quarter increase in net revenues, reaching $49.5 million.
The company has successfully reduced cash operating expenses by 43% quarter over quarter, which, combined with revenue growth, has impressed investors and analysts.
With guidance for full-year 2025 revenue of $170-$175 million and expectations to achieve operating profitability in 2026, Phathom Pharmaceuticals is seen as a strong candidate for continued growth and potential price appreciation.

Bearish· Jun 11

$PHAT's inability to break resistance at $9.50 suggests it's heading downwards.
Phathom Pharmaceuticals has no money, with a public offering expected soon, potentially leading to dilution.
The company's core metrics remain ugly, with unprofitability, over-leveraging, and cash burn, despite a recent exclusivity agreement.

Generated by AI

Topics

Of the messages about PHAT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	100%	25.47%
Announcements	—	—	0%	39.66%
Earnings	—	—	0%	16.24%
Analysts	—	—	0%	18.46%
Controversies	—	—	0%	0.17%
Macro	—	—	0%	0%

Jan 8

Phathom Pharmaceuticals priced a $130 million public offering of common stock and pre-funded warrants at $16 per share.
The company will use the funds from the offering for operations, research and development, and product rollout.
Phathom Pharmaceuticals' shares fell by 13.6% after pricing the stock offering at a discount.

Generated by AI

Community

Of the messages about PHAT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.68%	79.5%	54.53%
Newcomers	0%	11.32%	20.5%	45.47%

Regulars· Aug 4

The stock price may be due for a boost, potentially driven by upcoming trial results or a catalyst for the company's performance.
Analysts still have targets of $20 for the stock, despite the current sell-off, and the quarterly report did not fundamentally change the company's trajectory or results.
The recent selloff is seen as "comical" compared to the company's actual results and trajectory, with some investors hoping for the stock to stay around $8.5 for a couple of months.

Newcomers· Mar 2

Newcomers to the $PHAT community are discussing its market capitalization, specifically its value sitting at around $65k and how it's approaching its all-time high.
Recent investors are focused on Phathom Pharmaceuticals' upcoming Q4 2025 Earnings Call, with some speculating on what the company's financial results may reveal.
Many newcomers are concerned about the company's ability to maintain its current price level, as some have expressed skepticism about the stock's sustainability in reaching new all-time highs.

Generated by AI

Phathom Pharmaceuticals

Social

Sep 23

Bullish· Oct 30

Bearish· Jun 11

Jan 8

Regulars· Aug 4

Newcomers· Mar 2

Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD

Phathom starts phase 3 trial of Voquezna for heartburn relief

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT)

Phathom at Cantor conference: growth, access and new uses

Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Also Discussed

Phathom Pharmaceuticals, Inc.

Company Information

Location

Social

Sep 23

Bullish· Oct 30

Bearish· Jun 11

Jan 8

Regulars· Aug 4

Newcomers· Mar 2

Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD

Phathom starts phase 3 trial of Voquezna for heartburn relief

Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case (NASDAQ:PHAT)

Phathom at Cantor conference: growth, access and new uses

Leerink Partners Initiates Coverage on Phathom Pharmaceuticals With Market Perform, $10 PT

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Also Discussed